David Binder, MD
Radiation Oncology · Aurora, CONPI 1629463153
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.9%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by AstraZeneca at 27.9% of the total. Reporting peaked in 2021 at $358 and has fallen 51.1% since, to $175 in 2023.
Across 9 payments — averaging $90.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$228
- Foundation Medicine, Inc.$202
- Merit Medical Systems Inc$175
- GSK$120
- Johnson & Johnson$57
- Myriad Genetic Laboratories, Inc.$36
What the payments were for
- Consulting fees$17521%
- Speaking & faculty fees$20225%
- Food & beverage$44154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $228 |
| Foundation Medicine, Inc. | 1 | $202 |
| Merit Medical Systems Inc | 1 | $175 |
| GSK | 1 | $120 |
| Johnson & Johnson | 3 | $57 |
| Myriad Genetic Laboratories, Inc. | 1 | $36 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE$202
- FOUNDATIONONE HEME$202
- FOUNDATIONONE CDX$202
- FOUNDATIONFOCUS$202
- FOUNDATIONONE LIQUID CDX$202
- IMFINZI$125
- BLENREP$120
- LYNPARZA$103
How this compares
$818 in reported general payments places this provider in the 60th percentile of 105 radiation oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 33 | $556 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $284 |
| Dexamethasone | 19 | $174 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Aurora
- Meera PatelAurora$112K
- David RabenAurora$61K
- Christine FisherAurora$28K
- Karyn GoodmanAurora$12K
- Michelle LudwigAurora$4K
- Brian KavanaghAurora$2K
- Ryan LanningAurora$2K
- Dennis CarterAurora$955
- Blair MurphyAurora$500
- Katherine TzouAurora$439
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.